LONDON, Sept 11 (Reuters) - Data released on Monday by AstraZeneca (AZN.L) from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's (JNJ.N) rival treatment, analysts said.
A brief summary from the Phase 3 trial, called FLAURA2, was released in May, and the detailed data was presented on Monday in Singapore at the World Conference on Lung Cancer.
The FLAURA2 trial showed that when adding chemotherapy to Tagrisso, the risk of disease progression or death is reduced by 38% when compared to Tagrisso alone.
"With the strong FLAURA-2 data in hand and likely included in treatment guidelines soon, the hurdle is now pretty high in our view for MARIPOSA," the UBS note read.
Barclays analysts said the FLAURA2 trial data presented on Monday included doctor and patient surveys that showed a strong preference for the convenience of a single therapy compared with combinations.
Persons:
Johnson, Pascal Soriot, Michel Demare, Soriot, Maggie Fick, Emelia Sithole
Organizations:
AstraZeneca, Lung Cancer, Barclays, UBS, Reuters, Thomson
Locations:
Singapore, British, MARIPOSA